Streetbeat News

Analyst Ratings

DRI

TD Cowen analyst Andrew Charles has reiterated an 'Outperform' rating on Darden Restaurants (NYSE:DRI) and maintained a price target of $175.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:48 am

DIS

Needham analyst Laura Martin has reiterated a 'Hold' rating on Walt Disney (NYSE:DIS).

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:41 am

WING

Wedbush analyst Nick Setyan has upgraded Wingstop (NASDAQ:WING) from Neutral to Outperform and raised the price target from $180 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:40 am

RANI

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Rani Therapeutics Hldgs (NASDAQ:RANI) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:39 am

DRTS

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:38 am

APLS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $82.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:37 am

RVNC

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:36 am

PBYI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Puma Biotechnology (NASDAQ:PBYI) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:35 am

MRNS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:35 am

INDP

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Indaptus Therapeutics (NASDAQ:INDP) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 10:32 am